Alkem Laboratories Limited

BSE:539523 Stock Report

Market Cap: ₹648.9b

Alkem Laboratories Past Earnings Performance

Past criteria checks 5/6

Alkem Laboratories has been growing earnings at an average annual rate of 6.9%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 10.5% per year. Alkem Laboratories's return on equity is 18.1%, and it has net margins of 16.5%.

Key information

6.9%

Earnings growth rate

6.9%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate10.5%
Return on equity18.1%
Net Margin16.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Alkem Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:539523 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24128,31921,22331,2270
30 Jun 24127,31720,54230,6750
31 Mar 24126,67617,95830,3290
31 Dec 23126,34415,73230,3940
30 Sep 23123,51414,32929,9260
30 Jun 23119,90611,43330,0810
31 Mar 23115,9939,84229,7260
31 Dec 22111,80510,20827,0810
30 Sep 22107,58610,91726,5360
30 Jun 22104,79213,05125,7720
31 Mar 22106,34216,45625,7690
31 Dec 21103,42517,78022,6600
30 Sep 21100,41617,03322,0480
30 Jun 2196,04416,31121,1830
31 Mar 2188,65015,85019,8070
31 Dec 2087,21815,33821,2170
30 Sep 2085,97114,64821,0760
30 Jun 2084,98413,63620,8920
31 Mar 2083,44411,27120,8530
31 Dec 1981,48411,05720,3470
30 Sep 1978,9299,26219,8550
30 Jun 1975,4788,09819,2370
31 Mar 1973,5727,60518,7280
31 Dec 1870,1576,60217,7620
30 Sep 1868,3186,29317,4120
30 Jun 1867,7886,95517,2120
31 Mar 1863,9186,30916,5550
31 Dec 1760,0447,00915,1020
30 Sep 1757,2857,62614,6990
30 Jun 1755,0197,24814,2450
31 Mar 1756,8758,92013,9100
31 Dec 1656,9337,73213,4970
30 Sep 1654,9927,26712,9770
30 Jun 1652,4197,1089,4300
31 Mar 1649,2487,41611,6990
31 Dec 1547,9758,18915,267220
30 Sep 1544,5567,22715,252291
30 Jun 1540,4595,78111,940150
31 Mar 1537,4343,9169,0320
31 Mar 1431,1914,35310,466210

Quality Earnings: 539523 has high quality earnings.

Growing Profit Margin: 539523's current net profit margins (16.5%) are higher than last year (11.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 539523's earnings have grown by 6.9% per year over the past 5 years.

Accelerating Growth: 539523's earnings growth over the past year (48.1%) exceeds its 5-year average (6.9% per year).

Earnings vs Industry: 539523 earnings growth over the past year (48.1%) exceeded the Pharmaceuticals industry 20.4%.

Return on Equity

High ROE: 539523's Return on Equity (18.1%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 05:52
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alkem Laboratories Limited is covered by 35 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Prashant NairAmbit Capital
Shrikant AkolkarAngel Broking Private Limited
null nullAntique Stockbroking Ltd.